News
2d
Pharmaceutical Technology on MSNGSK acquires efimosfermin alfa from Boston Pharma for $2bn"GSK acquires efimosfermin alfa from Boston Pharma for $2bn" was originally created and published by Pharmaceutical ...
London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...
GSK plc announced the completion of its previously announced acquisition of efimosfermin alfa from Boston Pharmaceuticals. Efimosfermin is a phase III-ready, potential best-in-class investigational ...
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...
Hosted on MSN1mon
GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2B - MSNBritish pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...
GSK GSK-1.00 % decrease; red down pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs.
Boston Pharmaceuticals licensed the medicine from Novartis in 2020, with GSK now on the hook for success-based milestone payments and tiered royalties to the Swiss drugmaker.
BOSTON, June 9, 2025 – The Renaissance Boston Seaport District recently debuted its stunning new rooms… Scouting America is proud to announce that Bob Rivers, Executive Chair and Chair of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results